Compare McDonald's Corp (MCD) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McDonald's Corp vs Natera Inc. Common Stock — how do they compare? McDonald's Corp trades at $239.47 (market cap $166.87B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: McDonald's Corp is far larger — about 2.9× Natera Inc. Common Stock's market cap, and McDonald's Corp pays a 3.27% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold McDonald's Corp for 165 Days and Natera Inc. Common Stock for 0 Days on average.
| MCD | NTRA | |
|---|---|---|
Market Cap | $166.87B | $57.03B |
Volume | 4,543,119 | 1,131,157 |
Sector | Consumer Cyclical | Health |
52-Week High | $341.06 | $425.64 |
52-Week Low | $230.88 | $179.42 |
Typical Hold Time | 165 Days | 0 Days |
Enterprise Value | $220.64B | $56.18B |
Dividend Yield | 3.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McDonald's (MCD) trades at $235.65, up 0.18% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong Q2 2026 EPS of $3.38, beating expectations, and maintains robust profitability with a 31.72% net income margin. Recent news highlights McDonald's new 'NEXT' growth strategy focusing on automation and menu innovation to win back customers amid competitive pressures.
The stock offers a compelling long-term opportunity with 58.7% analyst buy ratings and a $284.70 consensus price target, representing 21% upside. Key risks include inflationary pressures on franchisee margins and high debt levels. The current valuation at 19.16x P/E appears reasonable given the company's stable cash flows and dividend consistency.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
